News

February 13, 2023

Cellphire Therapeutics Published in Journal of Cardiothoracic and Vascular Anesthesia

Cellphire Therapeutics is proud to announce the publication of “In Vitro Treatment of Extracorporeal Membrane Oxygenation (ECMO) Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets” in the Journal of Cardiothoracic and Vascular Anesthesia.

December 20, 2022

Cellphire Therapeutics Issued New Core Technology Patent (Materials and Methods for Producing Blood Products)

Cellphire Therapeutics is excited to announce the United States Patent Office (USPTO) issued a patent, entitled Materials and Methods for Manufacturing Blood Products (Patent 11,529,587 B2 ('587 Patent) covering a new innovation in the method used to produce Thrombosomes®.

May 2, 2022

Cellphire Therapeutics Names Anya Derbij, MD as Vice President of Clinical Operations

Dr. Derbij has worked for over 20 years in industry and joins the team as Vice President of Clinical Operations after successfully managing a pivotal trial in ophthalmic gene therapy during the worst of the COVID-19 pandemic.

March 31, 2022

Cellphire Therapeutics Treats First Patient in Phase 2/3 Cryopreserved Platelets Clinical Trial

Cellphire Therapeutics announced today that the 1st patient has been treated in its Phase 2/3 clinical trial, Randomized Controlled Trial Comparing Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery (CRYPTICS).

February 8, 2022

Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors

Announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors.

January 12, 2022

Cellphire Therapeutics Appoints Roy A. Beveridge, M.D. to Scientific Advisory Board

Announced today the appointment of Roy A. Beveridge, M.D. to Scientific Advisory Board

December 20, 2021

Cellphire Therapeutics Names W. Allan Alexander, MD as Chief Medical Officer

Announced today the appointment of W. Allan Alexander, MD as the company’s Chief Medical Officer, effective immediately.

November 8, 2021

Cellphire Therapeutics Names Angie Howerton as Vice President of Finance, Controller and Treasurer

Ms. Howerton brings 25-years of progressive experience with a range of companies. Before joining Cellphire, she held leadership roles at ExeGi Pharma, Thermo Fisher Scientific, and MTI-GlobalStem.